Recent News

Connect with us

521 News Items found
Alexander Rudensky
Harmful Immune Reactions Might One Day Be Curbed with Cell-Based Therapy

A team of researchers led by Memorial Sloan Kettering immunologist Alexander Rudensky has gained new understanding about regulatory T cells -- a subtype of immune cells that suppresses the immune system's reactivity.
Memorial Sloan Kettering Researchers Are 2010 Rock Stars of Science

Three Memorial Sloan Kettering Cancer Center investigators -- including the Center's new President, Craig B. Thompson -- have been featured with singer-songwriter Debbie Harry to lead the Geoffrey Beene Gives Back® 2010 Rock Stars of Science™ campaign in <i>GQ</i> magazine's December "Men of the Year" issue.
Hedvig Hricak (left) and David Scheinberg are members of the new Nanotechnology Center's executive committee, which Dr. Scheinberg chairs.
New Nanotechnology Center Combines Cutting-Edge Science with Memorial Sloan Kettering's Expertise in Patient Care

To take advantage of the growing field of nanotechnology, Memorial Sloan Kettering has established a Nanotechnology Center.
New Opportunities for Collaboration and Translation

As construction began on the Mortimer B. Zuckerman Research Center, SKI adopted new ways to advance therapeutic innovation at Memorial Sloan Kettering.
Zvi Fuks
Zvi Fuks Elected to the Institute of Medicine

Zvi Fuks has been elected a member of the Institute of Medicine, one of the highest honors in the fields of health and medicine.
Summer Students' Research Recognized at National Conference

Three 2010 summer students won poster awards at the Annual Biomedical Research Conference for Minority Students in November.
Novel Genetic Mutation that Causes the Most Common form of Eye Cancer Discovered

An international, multi-center study has revealed the discovery of a novel oncogene that is associated with uveal melanoma, the most common form of eye cancer. Researchers have isolated an oncogene called GNA11 and have found that it is present in more than 40 percent of tumor samples taken from patients with uveal melanoma.
Alexander Rudensky
An Interview With Alexander Rudensky

A member of the Sloan Kettering Institute's Immunology Program and a Howard Hughes Medical Institute investigator, Alexander Rudensky is fascinated by how a specific type of white blood cells called regulatory T cells regulates our immune system.
Samuel Danishefsky
Memorial Sloan Kettering Enters Agreement to Develop New Cancer Drug

As part of a commitment to seek new and better treatments for cancer patients, Memorial Sloan Kettering Cancer Center and Bristol-Myers Squibb are collaborating to bring a potential new cancer drug called iso-fludelone, or KOS-1803, into clinical trials.
Pictured: Eric C. Holland
Researchers Discover Genetic Changes That Make Some Forms of Brain Cancer More Aggressive Than Others

A multi-institutional team led by investigators from Memorial Sloan Kettering Cancer Center has published a study that provides new insight into genetic changes that make some forms of glioblastoma, the most common type of primary brain cancer, more aggressive than others and explains why they may not respond to certain therapies.